Study name: Global Advanced/Adjuvant Stomach Tumor Research through International Collaboration 2nd Round (GASTRIC 2nd Round)

1. Purpose of this project:

The following research objectives are analyzed:

- Efficacy of systemic first or second lines treatment and predictive factors of response to treatment
- Efficacy of anti VEGF / EGFR targeted treatments
- Non-inferiority of S-1, capecitabine and 5FU based regimen
- Efficacy of Irinotecan-based regimen
- Surrogacy of several endpoints (PFS, ORR, etc.) on OS

2. Target trials:

The GASTRIC group will contact and ask the collaboration with investigators (see the attached 62papers).

The following items are collected:

TRIAL DATA

Trial name	character
Sponsor name	character
Inclusion criteria of participants to be enrolled	Character
Name of the principal investigator	character
Study design	Superiority / Non-inferiority
Accrual period	DD/MM/YY to DD/MM/YY
Follow-up period	DD/MM/YY to DD/MM/YY

Definition of progression in the protocol	character

For each patient is needed:

RANDOMIZATION

Unique patient identification	character
Allocated treatment arm	1 to n (n=number of treatment arms)
Date of randomization	dd/mm/yyyy
Excluded of published analysis	
Yes	1
No	2
If yes, please specify the reasons	character

BASELINE PATIENT CHARACTERISTICS

Date of birth	dd/mm/yyyy

or age at inclusion	or number
Unknown	99
Sex	
Male	1
Female	2
Unknown	99
Performance Status: code as convenient but supply details of the Performance status scale used. Suggested coding if WHO/ECOG coding used:	
ECOG 0	0
ECOG 1	1
ECOG 2	2
ECOG 3	3
ECOG 4	4
Unknown	99
Karnofsky	0-100%

DISEASE CHARACTERISTICS AT PATIENT ENTRY

Disease status <u>at study entry</u>	
Locally advanced	1
Metastatic	2
Locally recurrent	3
Unknown	99
Primitive site	
stomach	1
cardia	2
gastro-oesophagus junction	3
other	4
unknown	99
Number of organs involved <u>at study entry</u>	1 to 10
Unknown	99
(multiple metastases in the same organ should be counted as only one organ involved)	
Location of metastases	
None	Y/N
Liver	Y/N
Lung	Y/N
Peritoneum	Y/N
Stomach	Y/N

Bone	Y/N
Brain	Y/N
Other localization …	
unknown	99
Ascites	
Yes	0
No	1
Unknown	99
Histology	
Diffuse	1
Intestinal	2
Other	3
Unknown	99

DISEASE CHARACTERISTICS AT PATIENT ENTRY (CONTINUED)

TNM (Precise tumour staging system used, Table 1)	
Primary tumour <u>at patient entry</u>	
T0	0
T1 (includes T1a, T1b)	1
T2	2
T3	3
T4(includes T4a, T4b)	4
TX	5
Tis	6

Unknown	99
Regional lymph nodes <u>at patient entry</u>	
N0	0
N1	1
N2	2
N3(Includes N3a, N3b)	3
NX	4
Unknown	99
Distant metastases <u>at patient entry</u>	
M0	0
M1	1
MX	2
Unknown	99
Stage <u>at patient entry</u>	
Stage Ia	1
Stage Ib	2
Stage II	3
Stage IIIa	4
Stage IIIb	5
Stage IV	6
Unclassifiable	7
Unknown	9
HER2 status	

negative	1
positive	2
unknown	99
Other molecular characterization of the tumour whenever available CDH1, microsatellite instability, DNA repair enzyme deficiency (Lynch syndrome) etc.	
Presence of measurable disease <u>at entry (based on the RECIST)</u>	
Yes	1
No	2
Unknown	99

PREVIOUS TREATMENTS FOR STOMACH CANCER

Prior gastrectomy	
Yes	0
No	1
Unknown	99
Date of surgery if available	dd/mm/yyyy
Specify operative procedure	
D0	0
D1	1
D2	2
D3	3

Unknown	99
Prior radiotherapy	
Yes	0
No	1
Unknown	99
Date of radiotherapy if available	dd/mm/yyyy
Prior systemic agents for <u>advanced</u> disease	
Number of lines before entering this trial	
0 (this protocol investigate 1st line trt)	0
1 (patient had one previous line of metastatic trt	1
2 etc.	2
Unknown	99
Specify chemotherapy regimens	
Progression-free interval for the prior line (if any)	1-xx
Unknown	0

TREATMENT IN THE CLINICAL TRIAL

Date start of chemotherapy	dd/mm/yyyy
Unknown	99
Date end of treatment	dd/mm/yyyy
Unknown	99

FOLLOW-UP

Status at last follow-up (updated if possible)	
Alive	0
Dead	1
Date of last follow-up (Date of death or date of last visit, updated if possible)	dd/mm/yyyy
Cause of death, if applicable	
Clearly disease related	1
Clearly toxicity related	2
Disease progression and toxicity	3
Non disease, non toxicity	4
Unknown	99
Progression of gastric cancer	
Yes	1
No	2
Unknown	99

Assessment of progression	
Imaging	1
Clinical judgment without imaging	2
Unknown	99
Date of progression of gastric cancer cancer (or date of last visit if free of progression, updated if possible)	dd/mm/yyyy
Cut-off date for PFS and OS endpoints	dd/mm/yyyy

Tumor response (best overall response during follow-up)	
Complete response	1
Partial response	2
Stable Disease	3
Progressive Disease	4
Unknown	9
Date of tumor response	dd/mm/yyyy
Reason of treatment discontinuation	
Disease progression	1
Adverse event including toxic death	2
Other reason	3
Unknown	99
Quality of life assessment	
Tests results	1
No test results	2

Unknown	99
Grade 3-4 toxicity	
Yes	1
No	2
Unknown	99

POST PROGRESSION

Therapy after treatment discontinuation	
Yes	1
No	2
Unknown	99
If yes, specify	character

3. Steering committee and secretariat

Data needed for all objectives will be centrally collected using the same process, the same data management rules and the same data storage. European and American trials will be collected by the French secretariat. Asian trials will be collected by the Japanese secretariat.

STUDIES FROM EUROPE AND USA	**STUDIES FROM ASIA , AUSTRALIA**
Xavier PAOLETTI	Koji OBA
Department of Biostatistics and Epidemiology Gustave Roussy Cancer Campus	Department of Biostatistics, School of Public Health,Graduate School of Medicine, The University of Tokyo
114, avenue Eduard Vaillant	5F, Annex of Building 3, Faculty of Medicine

94805 Villejuif Cedex France TEL: (33) [0] 1 42 11 65 64 FAX: (33) [0] 1 42 63 68 gastric@gustaveroussy.fr	7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033 JAPAN TEL: (81) [0] 3 58 41 35 19 FAX: (81) [0] 3 38 14 27 79 oba@epistat.m.u-tokyo.ac.jp

Other members worked as a steering committee are as follows:

Name	Affiliation		Role
Yung-Jue Bang	Seoul University	Professor	Steering Committee
Harry Bleiberg	N/A	N/A	Steering Committee
Olivier Bouche	Centre Hospitalier Universitaire Robert Debré	Professor	Steering Committee
Tomasz Burzykowski	Hasselt University	Professor	Steering Committee
Marc Buyse	IDDI	Directer	Steering Committee
Michael Ducreux	Institut Gustave-Roussy	Professor	Steering Committee
Stefan Michiels	Institut Gustave Roussy	Senior Statistician	Steering Committee
Markus Moehler	Johannes-Gutenberg University	Professor	Steering Committee
Satoshi Morita	Kyoto University	Professor	Steering Committee
Yasuo Ohashi	Chuo University	Professor	Steering Committee
Junichi Sakamoto	Tokai Central Hospital		Steering Committee
Mitsuru Sasako	Hyogo College of Medicine	Professor	Steering Committee
Kohei Shitara	National Cancer Center East		Steering Committee
Erik VanCutsem	University Hospital Gasthuisberg	Professor	Steering Committe

4. Person in charge of data management and place

- Koji OBA
- Department of Biostatistics, School of Public Health,Graduate School of Medicine, The University of Tokyo
- 5F, Annex of Building 3, Faculty of Medicine 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033 JAPAN

5. Project period

   From 1/1/2016 to 3/31/2020

6. Others

   These development will be conducted using completely anonymized data. If requests from the participants or agents, the project stop to use or provide data or information which enable identification of them to other institutions. Please contact to;

- Koji OBA
- Department of Biostatistics, School of Public Health,Graduate School of Medicine, The University of Tokyo
- 5F, Annex of Building 3, Faculty of Medicine 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033 JAPAN

Appendix: Eligible studies

No	1st author	PubYear	Journal
1	Moehler M	2010	Ann Oncol.
2	Ford HE	2014	Lancet Oncol.
3	Nishikawa K	2015	Eur J Cancer.
4	Nishikawa K	2012	Gastric Cancer
5	Wilke H	2014	Lancet Oncol.
6	Fuchs CS	2014	Lancet
7	Yoon HH	2016	Ann Oncol.
8	Guimbaud R	2014	J Clin Oncol.
9	Koizumi W	2014	J Cancer Res Clin Oncol.
10	Tanabe K	2015	Ann Oncol.
11	Boku N	2009	Lancet Oncol.
12	Komatsu Y	2011	Anticancer Drugs.
13	Sugimoto N	2014	Anticancer Res
14	Shen L	2015	Gastric Cancer
15	Bang YJ	2010	Lancet
16	Ohtsu A	2011	J Clin Oncol.

17	Higuchi K	2014	Eur J Cancer.
18	Hironaka S	2013	J Clin Oncol.
19	Yamada Y	2015	Ann Oncol.
20	Narahara H	2011	Gastric Cancer
21	Thuss-Patience PC	2011	Eur J Cancer.
22	Eatock MM	2013	Ann Oncol.
23	Iveson T	2014	Lancet Oncol.
24	Doi T	2015	NCT02137343
25	Catenacci D	2017	Lancet Oncol.
26	Waddell T	2013	Lancet Oncol.
27	Ajani JA	2010	J Clin Oncol.
28	Satoh T	2014	Gastric Cancer
29	Roth A	2010	NCT01123473
30	Kim YS	2014	Cancer Chemother Pharmacol.
31	Sym SJ	2013	Cancer Chemother Pharmacol.
32	Satoh T	2014	J Clin Oncol.
33	Hecht	2016	J Clin Oncol.
34	Mochiki E	2012	Br J Cancer.

35	Li J	2013	J Clin Oncol.
36	Gubanski M	2010	Gastric Cancer
37	Du F	2015	Medicine
38	Rao S	2010	Ann Oncol.
39	Lordick F	2013	Lancet Oncol.
40	Glenjen N	2012	ASCO
41	Ohtsu A	2013	J Clin Oncol.
42	Roy AC	2013	Ann Oncol.
43	Wang X	2013	Clin Transl Oncol.
44	Kang YK	2009	Ann Oncol.
45	Yi JH	2012	Br J Cancer.
46	Lee JK	2008	Br J Cancer.
47	Yun J	2010	Eur J Cancer.
48	J A Kim	2011	Cancer Chemother Pharmacol.
49	VanCutsem E	2015	Ann Oncol.
50	Koizumi W	2008	Lancet Oncol.
51	Richards D	2013	Eur J Cancer.
52	Kim GM	2012	Eur J Cancer.

53	Jeung HC	2011	Cancer
54	Huang D	2013	Eur J Cancer.
55	Boukovinas I	2009	ASCO
56	Kang JH	2012	J Clin Oncol.
57	Roy AC	2012	Br J Cancer.
58	Li JY	2016	World Chinese J Digestorogy
59	Zhao WY	2011	Zhonghua Zhong Liu Za Zhi
60	Tsuburaya A	2012	BMC Cancer
61	Koizumi W	2013	Br J Cancer.
62	Hironaka S	2016	Lancet Oncol.